Calyxt Announces Upsizing and Pricing of Follow-On Offering
18 5월 2018 - 9:50PM
Business Wire
Cellectis S.A. (NASDAQ: CLLS – EURONEXT GROWTH: ALCLS) and
Calyxt, Inc. (NASDAQ:CLXT) announced that the price of Calyxt’s
follow-on public offering of 3,600,000 shares of Calyxt’s common
stock launched May 15, 2018 has been set today at $15.00 per share,
representing gross proceeds to Calyxt of $54.0 million. Due to
demand, this offering was upsized from the previously announced
3,050,000 shares to accommodate Cellectis to buy 550,000
shares.
In connection with the offering, Calyxt granted the underwriters
a 30-day option to purchase up to an additional 457,500 shares of
Calyxt’s common stock. The closing of the offering is expected to
occur on May 22, 2018, subject to customary closing conditions.
Calyxt is a consumer-centric food- and agriculture-focused
company. Following the offering, Cellectis will own approximately
71.6% of Calyxt’s outstanding shares of common stock.
Citigroup, Goldman Sachs & Co. LLC and Jefferies are acting
as book-running managers for the offering. Wells Fargo Securities
is acting as lead manager and BMO Capital Markets Corp. is acting
as co-manager.
A registration statement on Form S-1 relating to these
securities has been filed with the U.S. Securities and Exchange
Commission and was declared effective on May 17, 2018. This
offering will be made only by means of a prospectus. A copy of the
prospectus may be obtained from Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood,
NY 11717, or by telephone at (800) 831-9146; Goldman Sachs &
Co. LLC, Attention: Prospectus Department, 200 West Street, New
York, NY 10282, or by telephone at (866) 471-2526, or by facsimile
at (212) 902-9316, or by email at prospectus-ny@ny.email.gs.com; or
Jefferies LLC, Attention: Equity Syndicate Prospectus Department,
520 Madison Avenue, 2nd Floor, New York, NY 10022, or by telephone
at (877) 547-6340, or by e-mail at
Prospectus_Department@Jefferies.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20180518005308/en/
For CalyxtMedia contactsJennifer Moore, VP
CommunicationsPhone: 917-580-1088email: media@calyxt.comorCaitlin
Kasunich / Nick OpichKCSA Strategic Communications212.896.1241 /
212.896.1206email: ckasunich@kcsa.com /
nopich@kcsa.comorInvestor Relations contactSimon Harnest, VP
Corporate Strategy and FinancePhone: 646-385-9008email:
simon.harnest@calyxt.com
Akari Therapeutics Plc (NASDAQ:CLTX)
과거 데이터 주식 차트
부터 8월(8) 2024 으로 9월(9) 2024
Akari Therapeutics Plc (NASDAQ:CLTX)
과거 데이터 주식 차트
부터 9월(9) 2023 으로 9월(9) 2024